0000000000059877

AUTHOR

Sherko Kümmel

showing 5 related works from this author

Metastatic pattern of breast cancer according to immunohistochemical defined subtypes in the transitional phase of adjuvant trastuzumab treatment.

2014

e11581 Background: Prognosis of early breast cancer (BC) differs significantly upon subtypes (ST). Treatment with adjuvant trastuzumab improves outcome of HER2 overexpressing BC, however, less in k...

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentmedicine.diseaseTransitional phaseBreast cancerOncologyTrastuzumabInternal medicineMedicineImmunohistochemistryskin and connective tissue diseasesbusinessneoplasmsAdjuvantmedicine.drugEarly breast cancerJournal of Clinical Oncology
researchProduct

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update

2021

Geburtshilfe und Frauenheilkunde 81(10), 1112-1120 (2021). doi:10.1055/a-1499-8431

medicine.medical_specialtyAxillary lymph nodesBreast surgerymedicine.medical_treatmentMammakarzinomBreast cancerbreast cancerMaternity and MidwiferyAdjuvant therapymedicineddc:610GebFra ScienceStage (cooking)Sentinel-Lymphknoten-Entfernungtargeted axillary dissectionsentinel LNEneoadjuvante Chemotherapiebusiness.industryObstetrics and Gynecologymedicine.diseaseRadiation therapyDissectionAxillamedicine.anatomical_structuregezielte axilläre DissektionRadiologybusinessRecommendation/Empfehlungneoadjuvant chemotherapy
researchProduct

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Posit…

2015

Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial. Patients and Methods GeparSixto investigated the effect of adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response (pCR). A total of 580 tumors were evaluated before random assignment for stromal TILs and lymphocyte-predominant BC (LPBC). mRNA expression of immune-activating (CXCL9, …

AdultOncologyCancer Researchmedicine.medical_specialtyStromal cellReceptor ErbB-2medicine.medical_treatmentAntineoplastic AgentsTriple Negative Breast NeoplasmsCarboplatinchemistry.chemical_compoundLymphocytes Tumor-InfiltratingPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansAgedRandomized Controlled Trials as TopicChemotherapybusiness.industryTumor-infiltrating lymphocytesCancerFOXP3Middle AgedPrognosismedicine.diseaseNeoadjuvant TherapyCarboplatin3. Good healthCD8AGene Expression Regulation NeoplasticOncologychemistryChemotherapy AdjuvantCXCL9FemalebusinessJournal of Clinical Oncology
researchProduct

Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice: First interim analysis of the National Non-I…

2016

581Background: In 2013 a subcutaneous (SC) formulation of trastuzumab (T) was approved based on non-inferiority to intravenous (IV) T as proven in the HannaH trial. So far no data from the routine ...

OncologyCancer Researchmedicine.medical_specialtybusiness.industryInterim analysisSurgeryOncologyTrastuzumabInternal medicineNon interventionalmedicineRoutine clinical practiceskin and connective tissue diseasesbusinessmedicine.drugEarly breast cancerJournal of Clinical Oncology
researchProduct

Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as firs…

2014

e12007 Background: B combined with chemotherapy (CT) significantly improves progression-free survival (PFS) and response rate (RR) vs CT alone in the first-line treatment of HER2-negative MBC. In a...

Response rate (survey)OncologyCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industryFirst linemedicine.medical_treatmentMedizinmedicine.diseaseMetastatic breast cancerSurgerychemistry.chemical_compoundOncologyPaclitaxelchemistryInternal medicinemedicineLong term outcomesCytotoxic T cellskin and connective tissue diseasesbusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct